These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7690335)

  • 21. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 35-year-old pregnant woman considering maternal serum screening and amniocentesis.
    Mennuti M
    JAMA; 1996 May; 275(18):1440-6. PubMed ID: 8618372
    [No Abstract]   [Full Text] [Related]  

  • 23. Maternal serum screening for neural tube defects and Down's syndrome.
    Robertson EF
    Med J Aust; 1991 Jul; 155(2):67-8. PubMed ID: 1713290
    [No Abstract]   [Full Text] [Related]  

  • 24. [Maternal serum screening for congenital abnormalities and Down syndrome in Sønderjylland County. Eight years of experience].
    Christiansen M; Petersen PL; Permin M; Larsen LA; Nørgaard-Pedersen B
    Ugeskr Laeger; 1999 Dec; 161(50):6928-34. PubMed ID: 10643380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Detection of chromosomal abnormalities using cordocentesis].
    Zolotukhina TV; Kuznetsov MI; Kostiuk EV; Shilova NV; Solonichenko VG
    Genetika; 1991 Aug; 27(8):1481-5. PubMed ID: 1722186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The triple-serum test for detection of Down syndrome and neural tube defects; the problem of a risk assessment test].
    van den Boer-van den Berg JM; Dupuis HM
    Ned Tijdschr Geneeskd; 1993 Jun; 137(26):1286-9. PubMed ID: 7688445
    [No Abstract]   [Full Text] [Related]  

  • 27. New trends in prenatal screening for chromosomal abnormalities.
    Addar MH
    Saudi Med J; 2000 May; 21(5):429-32. PubMed ID: 11500675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The identification of risk of spontaneous fetal loss through second-trimester maternal serum screening.
    Huang T; Owolabi T; Summers AM; Meier C; Wyatt PR
    Am J Obstet Gynecol; 2005 Aug; 193(2):395-403. PubMed ID: 16098861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prenatal screening for Down's syndrome with use of maternal serum markers.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
    N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maternal serum triple analyte screening in pregnancy.
    Graves JC; Miller KE; Sellers AD
    Am Fam Physician; 2002 Mar; 65(5):915-20. PubMed ID: 11898965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maternal serum screening and trisomy 16 confined to the placenta.
    Groli C; Cerri V; Tarantini M; Bellotti D; Jacobello C; Gianello R; Zanini R; Lancetti S; Zaglio S
    Prenat Diagn; 1996 Aug; 16(8):685-9. PubMed ID: 8878276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. False positivity of prenatal Down's syndrome and neural-tube tests in SLE.
    La Montagna G; Baruffo A; Buono G; Tirri R
    Lancet; 2000 Sep; 356(9236):1194-5. PubMed ID: 11030323
    [No Abstract]   [Full Text] [Related]  

  • 33. [The reliability of prenatal echographic studies of neural tube defects; a prospective study].
    Korenromp MJ; Kriek R; van den Born-van den Broek H; Stoutenbeek P; Bruinse HW
    Ned Tijdschr Geneeskd; 1993 Jun; 137(26):1298-302. PubMed ID: 7688447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prenatal diagnosis and screening: present and future.
    Brock DJ
    Prog Clin Biol Res; 1985; 163A():107-26. PubMed ID: 2578674
    [No Abstract]   [Full Text] [Related]  

  • 35. [Alpha-foetoprotein assessment in amniotic fluid for the detection of neural tube defects: limited added value beyond week 20 ultrasound; retrospective study].
    Mol BW
    Ned Tijdschr Geneeskd; 2008 Nov; 152(48):2639; author reply 2639. PubMed ID: 19102441
    [No Abstract]   [Full Text] [Related]  

  • 36. Placental mosaicism is associated with unexplained second-trimester elevation of MShCG levels, but not with elevation of MSAFP levels.
    Morssink LP; Sikkema-Raddatz B; Beekhuis JR; De Wolf BT; Mantingh A
    Prenat Diagn; 1996 Sep; 16(9):845-51. PubMed ID: 8905899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prenatal biochemical diagnostics of inborn developmental defects.
    Malbohan I; Fialová L; Mikulíková L; Hájek Z
    Sb Lek; 1994; 95(4):277-83. PubMed ID: 8867698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cystic hygroma and mid-trimester maternal serum screening.
    Celentano C; Prefumo F; Iezzi I; Guanciali-Franchi PE; Palka C; Liberati M; Rotmensch S
    J Med Screen; 2007; 14(3):109-12. PubMed ID: 17925081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-trimester sonographic detection of short rib-polydactyly syndrome type II (Majewski) following an abnormal maternal serum biochemical screening result.
    Chen CP; Chang TY; Tzen CY; Wang W
    Prenat Diagn; 2003 Apr; 23(4):353-5. PubMed ID: 12673646
    [No Abstract]   [Full Text] [Related]  

  • 40. [How women cope with the results of maternal serum screening for fetal neural tube defects and Down syndrome].
    Kamerbeek LI; Roelofsen EE; Beekhuis JR; Tijmstra T; Mantingh A
    Ned Tijdschr Geneeskd; 1993 Jun; 137(26):1308-11. PubMed ID: 7688449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.